Overview

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Status:
Completed
Trial end date:
2016-04-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo controlled, single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Bristol-Myers Squibb